CHICAGO–Roche/Genentech Inc. is riding the momentum created with the release of the EMILIA trial of its Herceptin-based antibody conjugate T-DM1 in late-stage breast cancer and preparing to conduct a study in early-stage breast cancer using a new accelerated approval pathway created by FDA, as part of the company’s “three-pronged” development strategy in breast cancer, Roche execs said during an analyst briefing at the annual American Society of Clinical Oncology meeting June 3.
A follow-on to the blockbuster Herceptin (trastuzumab), T-DM1 (trastuzumab emtansine) combines trastuzumab with a highly potent, cytotoxic agent called DM1, which is similar to taxane chemotherapy, connected by a stable linker
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?